Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
复制标题
DOI：
10.1182/blood-2008-10-185280
复制
发表时间：
2009-04-16
期刊：
影响因子：
20.3
通讯作者：
Bernstein, Steven H.
中科院分区：
文献类型：
--
作者：
Hilchey, Shannon P.;Hyrien, Ollivier;Bernstein, Steven H.
将利妥昔单抗（一种嵌合抗 CD20 单克隆抗体）纳入滤泡性淋巴瘤 (FL) 患者的治疗药物中，可显着改善此类患者的治疗结果。然而，尽管这种疗法几乎得到普遍应用，但其确切的作用机制尚未完全确定。一种提出的机制是“疫苗”效应，即利妥昔单抗杀死 FL 细胞导致引发 FL 特异性 T 细胞反应。据我们所知，利妥昔单抗甚至可以在患者中引起这种反应的证据从未被证明过。我们分析了 5 名 FL 患者在利妥昔单抗单药治疗前后对 FL 表达的免疫球蛋白的反应，发现在 5 名患者中，有 4 人在接受利妥昔单抗治疗后，FL 独特型特异性 T 细胞增加。因此，我们的数据为利妥昔单抗被动免疫疗法引发主动 FL 特异性细胞反应的能力提供了“原理证明”。 （血。2009；113：3809-3812）
The incorporation of rituximab, a chimeric anti-CD20 monoclonal antibody, into the therapeutic armamentarium for patients with follicular lymphoma (FL) has significantly improved treatment outcome for such patients. Despite the almost universal application of this therapy, however, its exact mechanism of action has not been completely defined. One proposed mechanism is that of a "vaccinal" effect, whereby FL cell kill by rituximab results in the elicitation of an FL-specific T-cell response. The demonstration that rituximab can even elicit such a response in patients has, to our knowledge, never been shown. We analyzed the response against the immunoglobulin expressed by the FL before and after rituximab monotherapy in 5 FL patients and found an increase in FL idiotype-specific T cells after rituximab in 4 of 5 patients. Our data thus provide "proof of principle" for the ability of passive immunotherapy with rituximab to elicit an active FL-specific cellular response. (Blood. 2009; 113: 3809-3812)